# A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC

> **NCT05236699** · PHASE2 · COMPLETED · sponsor: **Tongji Hospital** · enrollment: 23 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** DEB-TACE combined with Surufatinib and Camrelizumab

## Key facts

- **NCT ID:** NCT05236699
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-01-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236699, "A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05236699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*